Current Rating and Its Significance
MarketsMOJO’s 'Hold' rating for Medico Remedies Ltd indicates a balanced view of the stock’s prospects. It suggests that while the company demonstrates solid fundamentals and operational efficiency, there are factors that warrant caution, making it neither a strong buy nor a sell at this juncture. Investors should consider this rating as a signal to maintain existing positions rather than aggressively accumulate or divest shares.
Quality Assessment
As of 01 June 2026, Medico Remedies Ltd exhibits a good quality grade. The company’s management efficiency is reflected in a robust Return on Capital Employed (ROCE) of 15.04%, signalling effective utilisation of capital to generate profits. This level of ROCE is commendable for a microcap pharmaceutical entity, indicating disciplined capital allocation and operational competence.
Moreover, the company has consistently declared positive results over the last five consecutive quarters. Quarterly net sales have grown by 37.55% to ₹56.81 crores, while Profit Before Depreciation, Interest and Taxes (PBDIT) reached a peak of ₹7.15 crores. Profit Before Tax excluding other income also hit a high of ₹5.45 crores, underscoring steady earnings momentum.
Valuation Perspective
Currently, the valuation grade is assessed as fair. Medico Remedies trades at an enterprise value to capital employed ratio of 5.2, which is at a discount compared to its peers’ historical averages. This suggests that the stock is reasonably priced relative to the capital it employs to generate earnings.
Despite the stock’s underperformance in the past year, with a return of -12.29%, the company’s profits have risen by 30% over the same period. This divergence is reflected in a Price/Earnings to Growth (PEG) ratio of 1, indicating that the stock’s price is aligned with its earnings growth potential. Investors may find this valuation attractive if they prioritise earnings growth over short-term price movements.
Financial Trend Analysis
The financial trend for Medico Remedies Ltd is positive. The company maintains a low Debt to EBITDA ratio of 0.82 times, highlighting a strong ability to service debt and maintain financial stability. This conservative leverage profile reduces risk and provides flexibility for future growth initiatives.
However, long-term sales growth has been modest, with net sales increasing at an annual rate of 14.28% over the past five years. While this growth rate is respectable, it suggests that the company faces challenges in accelerating expansion in a competitive pharmaceutical sector.
Technical Outlook
From a technical standpoint, the stock is currently mildly bearish. Despite a strong one-day gain of 4.33% and a one-month rise of 17.34%, the six-month and year-to-date returns remain negative at -5.06% and -1.36% respectively. Over the last year, the stock has underperformed the broader market, with the BSE500 index declining by -1.44% compared to Medico Remedies’ -12.29% return.
This technical weakness may reflect investor caution amid sector volatility and the company’s microcap status, which often entails higher price fluctuations and liquidity constraints.
Investor Takeaway
For investors, the 'Hold' rating on Medico Remedies Ltd suggests a cautious approach. The company’s strong management efficiency, positive financial trends, and fair valuation provide a solid foundation. However, the mild bearish technical signals and moderate long-term growth temper enthusiasm.
Investors should monitor upcoming quarterly results and sector developments closely. Those with existing holdings may consider maintaining their positions while awaiting clearer signs of sustained price momentum or fundamental improvement. Prospective investors might prefer to observe the stock’s technical behaviour and broader market conditions before initiating new positions.
Our current Stock of the Month is out! This Large Cap from Automobiles - Passenger Cars emerged as the single best opportunity from our elite universe. Get the details now!
- - Current monthly selection
- - Single best opportunity
- - Elite universe pick
Company Profile and Market Context
Medico Remedies Ltd operates within the Pharmaceuticals & Biotechnology sector as a microcap company. Its promoter group holds the majority stake, providing stable ownership and strategic direction. The sector remains competitive and subject to regulatory scrutiny, which can impact growth trajectories and investor sentiment.
The company’s recent financial performance, including a 30% increase in profits over the past year, demonstrates resilience despite broader market headwinds. However, the stock’s price performance has lagged behind the market, reflecting investor caution and the challenges faced by smaller pharmaceutical firms in scaling operations.
Summary of Key Metrics as of 01 June 2026
• Mojo Score: 52.0 (Hold grade)
• ROCE: 15.04% (high management efficiency)
• Debt to EBITDA: 0.82 times (strong debt servicing ability)
• Net Sales Growth (5 years CAGR): 14.28%
• Quarterly Net Sales Growth: 37.55%
• PBDIT (Quarterly): ₹7.15 crores (highest recorded)
• PBT less Other Income (Quarterly): ₹5.45 crores (highest recorded)
• Stock Returns (1 Year): -8.91% (underperformed BSE500)
• Valuation: Fair, with EV/Capital Employed at 5.2 and PEG ratio of 1
Conclusion
Medico Remedies Ltd’s 'Hold' rating by MarketsMOJO reflects a nuanced view of the company’s current standing. The stock offers a blend of solid operational quality and fair valuation, balanced against technical caution and moderate growth prospects. Investors should weigh these factors carefully in the context of their portfolio objectives and risk tolerance.
Maintaining a watchful eye on quarterly earnings, sector developments, and price momentum will be crucial for making informed decisions regarding this pharmaceutical microcap.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
